Superior Th1 polarizing adjuvant
Potent alfa galactosyl ceramide analogues targeting invariant natural killer T-cells (iNKT) for selective boosting of cellular immunity.Best-in-class when benchmarked to other Th1-skewing Galcer analogues (IL-12/IFNg/IL-4 profiles). Less IL-4 production compared to aGalCer. No acute toxicity. Druggable profile and optimized for easy synthesis.Proof of conceptEnhanced primary and boosted CD8+ Tcell responses in immunised mice.
Novel class of superior Th1 polarizing glycolipids valuable as vaccine adjuvant or adjuvant therapy in oncology
· Contact name
Sven Arnouts
· E-mail
sven.arnouts@ugent.be
· Phone
+32 495 707 334
· Partner sought:
PartneringWe are actively seeking partners to develop or co-develop the Ghent University GalCer molecules to applications in the vaccine and/or oncology field.
Novel class of superior Th1 polarizing glycolipids valuable as vaccine adjuvant or adjuvant therapy in oncology.
Sven Arnouts
sven.arnouts@ugent.be
+32 495 707 334
en
ES